Human synovial sarcoma (SS), an aggressive soft-tissue tumor, affects predominantly the lower extremities of adolescents and adults 15-40 years of age (Weiss and Goldblum, 2001) . Despite the recent discovery that an SYT-SSX fusion gene is an SS-specific genetic alteration (Clark et al., 1994) , the precise molecular mechanisms underlying the tumorigenesis of SS remain to be elucidated. The SYT-SSX fusion product contains both activator and repressor elements for transcription and, as a net result, may exert a repressive effect on the transcription of certain tumor-suppressing genes. However, no specific targets of the SYT-SSX protein have been identified so far (dos Santos et al., 2001; Nagai et al., 2001) .
Among malignant tumors occurring in mesenchymal tissues, osteosarcomas, Ewing's sarcomas and rhabdomyosarcomas are generally sensitive to chemotherapy. Many other sarcomas, however, especially spindle-cell sarcomas such as SS, are refractory to any treatment (Crist et al., 2001; Ferguson and Goorin, 2001 ; Sarcoma Meta-analysis Collaboration, 1997; Wunder et al., 1998) . SS is a prototype of chemo-and radio-resistant soft-tissue tumors; therefore, novel treatment modalities must be developed to improve clinical outcomes for this disease.
In this report we describe characterization of a novel SS-specific gene, PDZK4, which was expressed exclusively in SS cells and normal fetal brain (PDZK4 was earlier designated by in-house number, C9473), isolated through analysis of genome-wide expression profiling by cDNA microarray representing 23 040 genes (Nagayama et al., 2002) . Transfection of small interfering RNA (siRNA) into SS cells in a gene-silencing experiment effectively suppressed growth. Thus, PDZK4 appears to play an important role in promoting growth of SS cells and might be a suitable candidate for molecular-targeted therapy.
Through our earlier genome-wide expression analysis of soft-tissue sarcomas using a cDNA microarray consisting of 23 040 genes, we first identified 26 genes upregulated in SS cells (Nagayama et al., 2002) , and then focused on one of them, Unigene ID number Hs.92732. Subsequent semiquantitative RT-PCR analysis confirmed that the expression of this gene of unknown function was specifically elevated in the tumors of all SS patients compared to mesenchymal stem cell as control (Nagayama et al., 2002) . The fulllength cDNA corresponding to Hs.92732 was isolated by exon-connection experiments using cDNAs prepared from surgical SS specimens, normal human adult tissues and fetal brain.
In the present work, scanning a 29-kb region of the X chromosome detected three different transcriptional variants consisting of 9, 8 and 6 exons ( Figure 1A ), which we designated Adult1, Fetal1/SS and Adult2/ Fetal2 respectively. Alternative splicing involved exons 2, 3 and 4, and the remaining exons were transcribed in all three variants. Exon 2 0 , characterizing the Fetal1/SS variant, was 18 bp shorter at the 3 0 end than exon 2 of the Adult1 variant. The full-length cDNA sequences of Adult1, Fetal1/SS and Adult2/Fetal2 variants contained 4241, 3980, and 3653 nucleotides, respectively. The ORF of the Adult1 variant started within exon 3, but the initiation sites of translation for both Fetal1/SS and Adult2/Fetal2 lay within exon 1.
To determine the expression pattern of each variant, we performed Northern blotting, using probes specific to each variant. As shown in Figure 1B , normal adult brain expressed two transcripts of about 4.5 and 3.8-kb, corresponding respectively to the Adult1 and Adult2/ Fetal2 variants depicted in Figure 1A , whereas normal fetal brain expressed 4.2-and 3.8-kb transcripts corresponding to the Fetal1/SS and Adult2/Fetal2 variants. Notably, the SS cell lines and surgical SS tissues expressed a single major transcript of 4.2-kb corresponding to the Fetal1/SS variant, which was sequenced and verified. We found no evidence of any genetic mutations. With regard to the tissue distribution of Hs.92732 variants, among the 16 normal adult tissues examined only adult brain expressed this gene, in the form of two transcripts corresponding to the Adult1 and Adult2/Fetal2 variants (data not shown). Additional Northern blotting, using probes specific to exons 9 and 2 0 , revealed that the Fetal1/SS variant was highly and exclusively expressed in SS tumor cells but was absent in normal adult pancreas, bone marrow, kidney, liver, lung and heart ( Figure 1C) and was not present, either, in carcinoma cells LoVo, SNU-C4, SW948, HCT116, WiDr, HCT15, HT29, SW480, or HeLa ( Figure 1D ).
According to their verified cDNA sequences, the three variants (Adult1, Fetal1/SS and Adult2/Fetal2) encode 673-, 769-and 660-amino-acid proteins respectively ( Figure 2A ). Since the peptide sequences predicted from exons 5-9 were identical among the three variants, the SMART program predicted that all of them would contain at least one PDZ domain in N-terminal region. However, it is likely that Fetal1/SS variant has an additional PDZ domain near the N terminus. Hence, we designated the Fetal1/SS variant as PDZK4 (PDZ domain-containing 4; the DNA sequence is available from GenBank under accession number AK091444) on the basis of the characteristics as described above, although Hs.92732 has been noted to associate with name LU1 protein.
To examine whether transcripts of the three variants could be translated, we performed in vitro translation experiments. As shown in Figure 2B , the Fetal1/SS and Adult2/Fetal2 transcripts were translated to gene products larger than predicted. There was no evidence of translation from the Adult1 variant, presumably because its translation-initiation site lies within exon 3 whereas the sites for the Fetal1/SS and Adult2/Fetal2 variants are in exon 1.
To confirm the pattern of each variant we transiently transfected expression plasmids into COS7 cells and confirmed expression by Western blotting ( Figure 2C ). As expected, the Adult1 variant was not detectable in mammalian cells by specific staining, whereas cells transfected with the Fetal1/SS or Adult2/Fetal2 variants expressed a protein of the same size as the product of translation achieved in vitro. Moreover, immmunocytochemical analysis using a myc-tag antibody or specific polyclonal antibody for Fetal1/SS protein showed that both Fetal1/SS and Adult2/Fetal2 products were enriched under the plasma membrane, although these products were barely detected in nucleus ( Figure 2D ). Therefore, these products may function like other PDZdomain containing proteins, by clustering various membrane-associated molecules under the plasma membrane.
To clarify a potentially tumorigenic role of the Fetal1/ SS transcript, we established two different siRNA expression vectors, psiU6BX-PDZK4-2032 and psiU6BX-PDZK4-2181 (Table 1) were grown in monolayers in appropriate media supplemented with 10% fetal bovine serum and 1% antibiotic/antimycotic solution, and maintained at 371C in air containing 5% CO 2 . Two primary tumor samples (SS582 and SS487) were snap-frozen in liquid nitrogen immediately after resection and stored at À801C until preparation of RNA. All samples were approved for our analysis by the ethical committee of the Faculty of Medicine, Kyoto University. Total RNAs were extracted from all cell lines and frozen surgical specimens using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. After treatment with DNase I (Nippon Gene, Osaka, Japan), mRNA was isolated with Micro-FastTrack (Invitrogen) following the manufacturer's instructions. A 1-mg aliquot of each mRNA, along with polyA ( þ ) RNAs isolated from normal adult human heart, brain, lung, liver, kidney, bone marrow and pancreas, and from normal fetal brain (BD Bioscience, Palo Atlo, CA, USA), were separated on 1% denaturing agarose gels and transferred on to nylon membranes. Hybridization with a random-primed, a 32 P-dCTP-labeled Hs.92732 cDNA probe was carried out according to the instructions for the Megaprime DNA labeling system (Amersham Bioscience, Buckinghamshire UK). Prehybridization, hybridization and washing were performed according to the supplier's recommendations. The blots were autoradiographed with intensifying screens at À801C for 3 days. Specific probes for exons 2 0 , 3 and 9 of Hs.92732 were prepared by PCR using the following primer sets: for exon 2 0 (224 bp), forward 5 0 -CGGGAAGGAGCTCTCCAAGC-3 0 and reverse 5 0 -GGATGACCATGGGCGGGGT-3 0 ; for exon 3 (240 bp), forward 5 0 -CGAGGGAGGACCCTCCT-3 0 and reverse 5 0 -GCGGTCAT GAGCCACCAG-3 0 ; and for exon 9 (1 400 bp), forward 5 0 -GTATGACGACCGACGACGAC-3 0 and reverse 5 0 -GTTCACACGTG CAAATCCTG-3 0 . (C) Distribution of Hs.92732 gene expression among SS tissue samples SS582 and SS487, cell lines SYO-1, YaFuSS and HS-SY-2, and normal organs (fetal brain, adult brain, pancreas, bone marrow, kidney, liver, lung and heart) by Northern-blot analysis using an exon 9-specific probe (as described in legend of (B)), showing the exclusive distribution of the Fetal1/SS variant in SS samples. (D) Northern blotting with an exon 2 0 -specific probe (as described in legend of (B)); the Fetal1/SS variant is expressed in SS cell lines SYO-1, HS-SY-2, and YaFuSS, but not in colon cancer cell lines LoVo, SNU-C4, SW948, HCT116, WiDr, HCT15, HT29, SW480 or a cervical adenocarcinoma cell line HeLa. These cell lines were also cultured with the conditions as described in legend of (B)
Upregulation of PDZK4 in synovial sarcomas S Nagayama et al caused by these siRNAs, we used PDZK4-negative cell line, T98G, and observed no effect of the siRNAs on cell growth of this cell line (Figure 3b, lower panel) . We then examined the oncogenic effect of PDZK4 by a colony formation assay using glioblastoma cell line T98G and COS7 cells in which no endogenous expression of PDZK4 was obtained (Figure 4a) . Overexpression of pcDNA3.1 (À)-PDZK4 produced a significantly higher number of colonies than the cells transfected with control plasmid (mock vector) (Figure 4b ). This result was confirmed in three independent experiments. Combining the data of siRNA experiments, PDZK4 is likely to function as oncogene and has a crucial role in carcinogenesis of this specific type of soft tissue tumor.
Although several regimens of chemotherapy for SS patients have been tried, clinical outcomes have not improved and alternative therapies must be developed (Antman et al., 1993; Patel et al., 1998; Frustaci et al., 2001; Edmonson et al., 2002) . SS is characterized biologically by the presence of a SYT-SSX fusion gene, a diagnostic marker that distinguishes SS from other spindle-cell sarcomas that resemble it morphologically (van de Rijn et al., 1999) . As the SS-specific fusion product is likely to be closely involved in tumorigenesis of SS, it could represent an ideal target for novel therapeutic agents. However, the signal pathway relevant to the SYT-SSX fusion protein remains to be clarified, and no functional inhibitors against the SYT-SSX fusion gene have been developed.
Among the three transcripts of Hs.92732 we isolated, Fetal1/SS and Adult2/Fetal2 transcripts were translated to gene products in vitro and confirmed by Western blotting of transient transfectants ( Figure 2C ). In view COS7-Fetal1/SS and the right panel; COS7-Adult2/Fetal2) were fixed with PBS containing 4% paraformaldehyde, and permeabilized with PBS containing 0.1% Triton X-100 at 41C for 2.5 min. The cells were covered with blocking solution (3% BSA in PBS) for 1 h at room temperature and incubated for 1 h at room temperature with a mouse anti-c-myc 9E10 antibody (diluted 1 : 1000) or a rabbit anti-PDZK4 (diluted 1 : 2000) in blocking solution. These antibodies were stained with a goat anti-mouse secondary antibody conjugated to Rhodamine or a goat anti-rabbit secondary antibody conjugated to FITC. Following nuclear staining with DAPI, the cells were visualized with a TCS SP2 Leica conforcal Microscope (Leica, Mannheim, Germany) Upregulation of PDZK4 in synovial sarcomas S Nagayama et al Figure 3 Growth-inhibitory effects of small-interfering RNAs (siRNAs) designed to reduce expression of PDZK4 in SS cells. Using an siRNA expression vector (psiU6BX3.0) carrying a U6 promoter and a neomycin-resistant gene, we constructed two different vectors against PDZK4 by inserting specific double-stranded oligonucleotides into the BbsI site of psiU6BX3.0 (psiU6BX-PDZK4-2032 and psiU6BX-PDZK4-2181). As a negative control we used psiU6BX-EGFP, a plasmid designed to suppress expression of EGFP. The sequence information on these siRNAs is given in Table 1 . SS cells from lines HS-SY-2 and YaFuSS, and a glioblastoma cell line T98G were collected by trypsinization; 1 Â 10 6 cells were resuspended into solution V buffer (Amaxa, Cologne, Germany) and separate samples were electroporated with 3 mg of each siRNA expression vector using Nucleofector (Amaxa) according to the T-01 program. (a) Semiquantitative RT-PCR showing suppression of endogenous expression of Fetal1/SS in SS cells (HS-SY-2 and YaFuSS) at 5-day cultures in selective medium containing neomycin after introduction of siRNAs into SS cells. b2MG was used as an internal control. A 3-mg aliquot of total RNA prepared from each cell line was reverse-transcribed for single-stranded cDNAs using oligo(dT) 12-18 primer and Superscript II (Invitrogen). Next, we performed semiquantitative RT-PCR using specific primers for the Fetal1/SS variant of Hs.92732 and for b2-microglobulin (b2MG) as an internal control, that is, forward primer in exon 2 0 of Hs.92732, 5 0 -CGGGAAGGAGCTCTCCAAGC-3 0 and reverse primer in exon 4, 5 0 -CATACTCCAGCTCATCCAAGC-3 0 ; primers forb2MG were forward, 5 0 -CACCCCCACTGAAAAAGATGA-3 0 and reverse, 5 0 -TACCTGTGGAGCAACCTGC-3 0 . (b) Effect of siRNA on growth of SS and glioblastoma cell lines. Upper panel; colony-formation assay demonstrating a decrease in the numbers of colonies by knockdown of PDZK4 expression in PDZK4 positive-cell lines, HS-SY-2 and YaFuSS. Lower panel; no knockdown effect on growth of PDZK4 negative-cell line, T98G. Transfectants expressing siRNAs were grown for 20 days in selective media containing 0.5 mg/ml of neomycin. After fixation with 4% paraformaldehyde, transfected cells were stained with Giemsa solution to assess colony formation. (c) MTT assay also revealing significant suppression of SS cell growth following introduction of siRNAs. After 14 days of culture in the neomycin-containing medium, MTT solution (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Sigma-Aldrich) was added at a concentration of 0.5 mg/ml. Following incubation at 371C for 4 h, acid-SDS (0.01 N HCl/10%SDS) was added; the suspension was mixed vigorously and then incubated overnight at 371C to dissolve the dark blue crystals. Absorbance at 570 nm was measured with a Microplate Reader 550 (Bio-Rad). Data are expressed as mean7s.d. and statistical analysis was performed by means of the Student's t-test Upregulation of PDZK4 in synovial sarcomas S Nagayama et al of the evidence regarding tissue distribution of Hs.92732 expression, the Fetal1/SS variant, termed PDZK4, should be a good candidate for development of molecular-targeted therapy, since its expression is restricted to SS and human fetal brain. In adult human brain, Adult1 and Adult2/Fetal2 variants are expressed as major transcripts, but expression of PDZK4 is barely detectable. The exclusive expression of this gene in neural tissues supports our earlier hypothesis that SS may originate from neural crest cells (Nagayama et al., 2002) . PDZ domains have been found in more than 200 proteins including many involved in cell signaling, although little is known about their precise function in vivo (Fanning and Anderson, 1999; Hung and Sheng, 2002) . Several functions have been postulated for PDZ domains: (i) correct spatial arrangement of membraneassociated proteins, including ion channels, receptors or other signaling molecules, under the plasma membrane (Pawson and Scott, 1997; Hirao et al., 2000) ; (ii) involvement in trafficking and/or endocytosis of transmembrane proteins (Cao et al., 1999; Xu et al., 2001) ; (iii) integration and organization of signal transduction to form a highly organized unit of signaling, the 'transducisome' (Tsunoda et al., 1997; Shoji et al., 2000; Bezprozvanny and Maximov, 2001) ; and/or (iv) establishment and maintenance of apicalbasal polarity in epithelial tissues (Ohno, 2001; Mizuno et al., 2003) .
Through genome-wide gene-expression profiles of soft-tissue sarcomas, we identified here PDZK4 that was specifically overexpressed in SS but undetectable in other spindle-cell sarcomas, including malignant fibrous histiocytomas and leiomyosarcomas (Nagayama et al., 2002) . It is noteworthy that expression patterns of the three Hs.92732 variants change between fetal and adult brain tissues, suggesting that expression of PDZK4 might be involved in growth of neural precursors. The second potential PDZ domain near the N-terminus of this tumor-and fetus-specific molecule may endow the Adult2/Fetal2 product with an additional function.
Gene-silencing effects using PDZK4 specific-siRNA and growth promoting effects by the exogenous PDZK4 expression strongly implied that PDZK4 promotes growth of SS cells (Figures 3 and 4) , although the mechanism involved remains to be elucidated. Furthermore, since the PDZK4 product locates under the plasma membrane, this protein should be able to serve as an adaptor or linker between trans-membrane and cytosolic proteins, recruiting cytosolic proteins to specific subcellular domains in the process. Therefore, identification of molecules that would interact specifically with PDZK4 may provide insights toward a better 4 mg/ml of neomycin, respectively. After fixation with 4% paraformaldehyde, transfected cells were stained with Giemsa solution to assess colony formation, and counted. The experiments were repeated three times using triplicate samples, and data are expressed as mean7s.d. and statistical analysis was performed by means of the Student's t-test understanding of this gene's involvement in cell survival. In particular, the possibility that PDZK4 is a downstream target in the signaling pathway of SYT-SSX fusion product should be examined.
In summary, we have isolated a novel SS-specific, growth-promoting gene, PDZK4, that was expressed exclusively in SS among the human tissues we examined. From the therapeutic perspective, this molecule is a promising candidate for development of new agents for treating SS patients. In addition, its discovery provides clues for further exploration of the pathogenesis of SS.
